Zydus Cadila Reels After Double FDA Warning
This article was originally published in PharmAsia News
Executive Summary
Shares of Cadila Healthcare were pounded on Indian bourses on New Year's Eve after the US FDA issued warning letters against two of the firm's Indian sites, though the company's top brass stressed that de-risking efforts, by way of site transfers for critical products, were already underway.
You may also be interested in...
Zydus Cadila Chief Passes On Baton To Scion
Cadila Healthcare’s scion Dr Sharvil Patel takes charge as managing director as the frontline Indian company transitions to its next phase of growth and aspires for a more innovation-driven avatar.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.